Obsessive-Compulsive Disorder (OCD) Drugs Market Analysis North America, Europe, Asia, Rest of World (ROW) - US, Germany, France, China, Japan - Size and Forecast 2024-2028

Obsessive-Compulsive Disorder (OCD) Drugs Market 2024-2028

The Obsessive-Compulsive Disorder (OCD) Drugs Market size is estimated to grow by USD 348.54 million at a CAGR of 5.93% between 2023 and 2028. 

Conventional therapies used to treat OCD are anti-anxiety, antipsychotic, and antidepressant drugs, along with behavioral therapies and psychotherapy. However, these medications and therapies are only for short-term treatment. In the long term, OCD can be managed but cannot be cured completely without patient compliance. Antidepressants classified as SRI have been used to treat OCD for many years. Hence, the Anafranil SRI molecule is considered the drug of choice for treating OCD. Anafranil was approved by the US FDA to treat OCD in adults and children aged ten and above. Similarly, to treat treatment-resistant depression, various vendors are developing new products. For instance, Jazz Pharmaceuticals plc offers LUVOX CR, which is available for patients with social anxiety disorder and OCD. Such launch and development of new molecules are expected to boost the market growth and trends during the forecast period.

Technavio has segmented the market into Product, Route Of Administration and Geography 

• The product  segment is classified into SSRI, TSA, and others
• The route of administration segment is classified into oral and parenteral
• The geography segment includes key regions such as North America, Europe, Asia, and Rest of World (ROW)

It also includes an in-depth analysis of market research and growth and trends along with challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.

What will be the size of the Obsessive-Compulsive Disorder Drugs Market During the Forecast Period?

To learn more about this report, Download Report Sample

Obsessive-Compulsive Disorder Drugs Market Segmentation by Product, Route Of Administration and Geography Analysis

Product Analysis 

SSRI

The market share growth by the SSRI segment will be significant during the forecast period. The availability of a large number of SSRIs in the market, such as fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram, and escitalopram driven the growth of the segment. These drugs act through selective inhibition of presynaptic serotonin or 5-hydroxytryptamine (5-HT) reuptake transport system, which increases the levels of serotonin in the brain. 

Get a glance at the market contribution of various segments Download PDF Sample

The SSRI was the largest and was valued at USD 388.38 million in 2018. SSRIs are the first-line treatment for OCD due to fewer side effects compared with TCA and other classes of drugs. For instance, unlike SSRIs, TCA causes severe withdrawal symptoms and suicidal risks. This is due to the selective inhibition of 5-HT reuptake in presynaptic junctions. Hence, SSRIs are preferred over TCA and other segment drugs in treating OCD. Among SSRIs, fluoxetine, sertraline, and fluvoxamine are approved for pediatric patients with OCD.  Major countries and some organizations, like the US, the European Union (EU), and Japan, have approved many generic versions due to the high demand for SSRIs. Some companies are developing controlled-release and sustained-release formulations of SSRIs. Such new drugs are expected to accelerate the growth of the global OCD drugs market during the forecast period.

Route Of Administration Analysis

Oral

One popular and useful way to administer drugs, including those used to treat OCD, is orally. Within the market for OCD pharmaceuticals, oral administration refers to taking medication by mouth; they are usually tablets, capsules, or liquid formulations. The active components required to treat OCD symptoms are present in these solid dose forms. Certain drugs are supplied in capsule form, which has a powdered or liquid drug within. The precise dosage and simplicity of ingesting are two benefits of using capsules. Although oral administration is commonly employed in the market for OCD medications, it is important to remember that other administration methods, such as intravenous or transdermal, may be taken into consideration depending on the needs of a particular patient and the medication's properties. The drug characteristics, the patient preferences, and the intended treatment all influence the route of administration that is selected. Therefore, the oral segment will witness high growth, which in turn will drive the growth of the global OCD drugs market during the forecast period.

Parenteral

When medication is administered parenterally, the digestive tract is skipped, and the drug is absorbed straight into the body. Parenteral administration is less common than oral administration in the context of OCD drug sales, but it can be used in certain situations. Subcutaneous, intramuscular, and intravenous injections are only a few of the injection routes that can be used for parenteral administration. The medicine is injected straight into a vein during intravenous delivery. Parenteral administration is not the preferred method for administering most OCD medications, but it might be taken into consideration in specific clinical scenarios. The patient's condition, the urgency of the treatment, and the particulars of the medication all play a role in the decision between oral and parenteral administration. Healthcare practitioners thoroughly consider these aspects to ascertain the best way to administer OCD medications in each unique situation. Hence, parenteral administration is less applicable in the global OCD

Regional Analysis

For more insights about the market share of various regions Download PDF Sample now!

North America is estimated to contribute 55% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period.  The obsessive-compulsive disorder (OCD) drugs market growth in North America is attributed to three major drivers, which include the growing incidence of OCD, government initiatives to combat OCD, and the availability of drugs. The rising incidence of OCD in the US and Canada is driving obsessive-compulsive disorder drugs market growth in North America. The presence of a large number of OCD drugs in the US and Canada is driving the obsessive-compulsive disorder drugs market in North America.

For instance, as of December 2021, the US FDA approved more than 150 products, including the NDA and ANDA versions of fluoxetine. Similarly, the US FDA approved more than 80 products, including the NDA and ANDA versions of paroxetine. Similarly, Apotex Inc. offers Paroxetine Hydrochloride Tablets USP for the treatment of OCD. Eli Lilly and Co. offers Prozac (fluoxetine) in 10, 20, and 40 mg capsules. Thus, the availability of a large number of drugs is expected to propel the regional OCD drugs market during the forecast period.

Buy Full Report Now

Key Obsessive-Compulsive Disorder Drugs Market Players 

Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The market report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:

Anant Pharmaceuticals Pvt. Ltd. - The company offers obsessive compulsive disorder drugs under the brand name of Celexa, and Luvox

• Alembic Pharmaceuticals Ltd.
• Apotex Inc.
• BrainsWay Ltd.
• Dellwich Healthcare LLP
• Eli Lilly and Co.
• Eridanus
• flamingopharma.com
• GlaxoSmithKline Plc
• H Lundbeck AS
• Jabs Biotech
• Jazz Pharmaceuticals Plc
• Kabir Lifesciences
• Lepu Medical Technology Beijing Co. Ltd.
• Lifecare Neuro Products Ltd.
• Novartis AG
• Omeros Corp.
• Pfizer Inc.
• SERVOMAX Ltd.
• Wellona Pharma
• Neurocon Inc.

Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.

Obsessive-Compulsive Disorder Drugs Market: Key Drivers, Trends, Challenges, and Customer Landscape

There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the market growth and forecasting along with key drivers, trends, and challenges. 

Key Obsessive-Compulsive Disorder Drugs Market Drivers

The rising prevalence of OCD is notably driving market growth. The prevalence of OCD is high in high-income countries due to the drastic change in the lifestyle of individuals. For instance, exposure to motion picture technologies provokes individuals about imaginary images, intrusive thoughts, and urges. OCD is considered the fourth most common mental disorder in high-income countries. OCD affects men, women, and children. It is most evident in childhood, adolescence, or early adulthood stages.

For instance, as per the NIH, approximately three million adults in the US have OCD. Among children and teenagers, at least one in 200 or 500,000 individuals have the disorder, and the number is almost the same as that of children with diabetes. Such a high prevalence of the disorder is expected to drive the growth of the global OCD drugs market during the forecast period.

Significant Obsessive-Compulsive Disorder Drugs Market Trends

Expanding research on first-in-class peptide therapeutics is an emerging trend shaping the market growth during the market forecast. The development of a new class of peptide therapeutics research is to enhance the bioavailability of the products and to address the unmet needs of OCD, such as the lack of new drugs. For instance, troriluzole is a third-generation tripeptide prodrug molecule that modulates the glutamate neurotransmitter in the human body. The prodrug form enhances the bioavailability of the riluzole by getting absorbed through the peptide transporter 1.

As a result, the troriluzole molecule is expected to be approved over the forecast period with improved pharmacological activity, safer dosage, and enhanced bioavailability. Similarly, Omeros Corp. developed a phase I molecule, OMS-527. Such new drug developments are expected to propel the growth of the market during the forecast period.

Major Obsessive-Compulsive Disorder Drugs Market Challenges

Adverse reactions to OCD drugs are a significant challenge hindering market growth. The low-quality, inexpensive kettle controls developed by the Chinese manufacturers are adversely affecting consumers' health. Owing to the rising number of issues from consumers and other global vendors in the market, the Chinese government has introduced regulations to improve the quality of such products. As a result, many Chinese products have been called off from the market.

Moreover, most of the prominent vendors have limited supply to commercial kitchens and underdeveloped regions, it is limiting the revenue flow in the market and limiting the entry of new vendors. Thus, the Increasing health concerns due to the poor quality of electric kettles will hamper the growth of the global kettle controls market during the forecast period. 

Buy Now Full Report

Key Obsessive-Compulsive Disorder Drugs Market Customer Landscape

The market analysis and report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the market report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.

Global Obsessive-Compulsive Disorder Drugs Market Customer Landscape

Segment Overview

The obsessive-compulsive disorder drugs Market forecasting report, market trends and analysis and market growth analysis by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028. 

• Product Outlook
  • SSRI
  • TSA
  • Others

• Route Of Administration Outlook
  • Oral
  • Parenteral

• Region Outlook
  • North America
    • The U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
    • Rest of Europe
  • Asia
    • China
    • India
  • Rest of World (ROW)
    • Brazil
    • Argentina 
    • Australia 

Obsessive-Compulsive Disorder Drugs Market Scope
Report Coverage	Details
Page number	159
Base year	2023
Historic period	2018-2022
Forecast period	2024-2028
Growth momentum & CAGR	Accelerate at a CAGR of 5.93%
Market growth 2024-2028	USD 348.54 million
Market structure	Fragmented
YoY growth 2023-2024(%)	5.18
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 55%
Key countries	US, Germany, France, China, and Japan
Competitive landscape	Leading companies, Market Positioning of companies, Competitive Strategies, and Industry Risks
Key companies profiled	Alembic Pharmaceuticals Ltd., Anant Pharmaceuticals Pvt. Ltd., Apotex Inc., BrainsWay Ltd., Dellwich Healthcare LLP, Eli Lilly and Co., Eridanus, flamingopharma.com, GlaxoSmithKline Plc, H Lundbeck AS, Jabs Biotech, Jazz Pharmaceuticals Plc, Kabir Lifesciences, Lepu Medical Technology Beijing Co. Ltd., Lifecare Neuro Products Ltd., Novartis AG, Omeros Corp., Pfizer Inc., SERVOMAX Ltd., Wellona Pharma, and Neurocon Inc.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Download Sample PDF at your Fingertips

What are the Key Data Covered in this Obsessive-Compulsive Disorder Drugs Market Research Report?

• CAGR of the market during the forecast period
• Detailed information on factors that will drive the growth of the  obsessive-compulsive disorder drugs market  between 2024 and 2028
• Precise estimation of the obsessive-compulsive disorder drugs market size and its contribution of the market in focus to the parent market
• Detailed analysis of customer landscape covering Diver of price sensitivity, Adoption of the lifecycle, and key purchase criteria 
• Companies landscape comparing criticality of inputs and factors of differentiation
• Exclusive Matrix on companies position and classification
• Accurate predictions about upcoming trends and changes in consumer behavior
• Growth of the market across North America, Europe, Asia, and Rest of World (ROW)
• Thorough analysis of the market’s competitive landscape and detailed information about companies
• Comprehensive analysis of factors that will challenge the growth of obsessive-compulsive disorder drugs market companies

We can help! Our analysts can customize this market research report to meet your requirements. Get in touch